Showing 1 - 8 of 8 Blood and Lymph Conditions

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >

Status: Enrolling

Investigator: Lawrence Rice

Study Coordinator: Minh Truong

Phone: 346.238.6403

Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be random ... Read more >

Status: Enrolling

Investigator: Lawrence Rice

Study Coordinator: Minh Truong

Phone: 346.238.6403

This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earli ... Read more >

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

Status: Open Not Enrolling

Investigator: Alpesh Shah

Study Coordinator: Patricia Brinegar

Phone: 713.441.3506

This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >

Status: Enrolling

Investigator: Alan Lumsden

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This prospective, multicenter, single-arm clinical study will further evaluate the safety and effectiveness of Cook's permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® ... Read more >

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remissi ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available